基于正痘病毒 A33/A35 表位定位筛选的人源抗体组合在小鼠中提供治疗保护
Human antibody combinations determined by epitope mapping of orthopoxvirus A33/A35 confer therapeutic protection in mice
研究通过对正痘病毒 A33/A35 进行表位定位,筛选出人源抗体组合,并在小鼠实验中显示该组合具有治疗保护作用,结果发表于 Science Translational Medicine 第 18 卷第 875 期。由于来源仅提供摘要,文中未列出具体抗体数量、攻毒模型、给药剂量与保护率等数据。
原文摘要
出版方登记 · CrossrefHuman infections with mpox virus (MPXV) since 2022 have resulted in more than 188,000 cases reported globally as of June 2026, highlighting the urgent need for effective therapeutics. Here, we recruited smallpox vaccinees and donors with incidental vaccinia virus (VACV) exposure and isolated a panel of human anti-A33/A35 monoclonal antibodies (mAbs) from the latter using recombinant MPXV A35 as a cross-reactive bait. These mAbs recognized four distinct nonoverlapping epitopes (epitopes 1 to 4) and one composite epitope (epitope 3 + 4) on MPXV A35 and exhibited cross-reactivity against multiple orthopoxviruses (OPXVs). Cryo–electron microscopy structural analysis revealed that the high-affinity epitope 3 + 4 mAb HD15 engages an epitope at the A35 dimer interface that is conserved across OPXVs. Combinations of mAbs targeting nonoverlapping epitopes mediated synergistic, Fc-dependent neutralization in vitro; conferred therapeutic protection against lethal VACV challenge; and reduced viral burden and disease severity after MPXV challenge in mice. Together, these findings establish a single-antigen, multiepitope strategy for the development of broadly protective therapeutics against OPXVs.
页面未能读取全文,以上为出版方登记的摘要;方法与图表见原文
来源:Science Translational Medicine · science.org